Global Immunotherapy Drugs for Multiple Myeloma
Table of Contents
2019-2024 Global Immunotherapy Drugs for Multiple Myeloma Market Report (Status and Outlook)
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Immunotherapy Drugs for Multiple Myeloma Market Size 2014-2024
- 2.1.2 Immunotherapy Drugs for Multiple Myeloma Market Size CAGR by Region
- 2.2 Immunotherapy Drugs for Multiple Myeloma Segment by Type
- 2.2.1 INF-α
- 2.2.2 IL-6
- 2.2.3 Rituximab
- 2.2.4 Other
- 2.3 Immunotherapy Drugs for Multiple Myeloma Market Size by Type
- 2.3.1 Global Immunotherapy Drugs for Multiple Myeloma Market Size Market Share by Type (2014-2019)
- 2.3.2 Global Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate by Type (2014-2019)
- 2.4 Immunotherapy Drugs for Multiple Myeloma Segment by Application
- 2.4.1 Hospital
- 2.4.2 Drug Center
- 2.4.3 Clinic
- 2.4.4 Other
- 2.5 Immunotherapy Drugs for Multiple Myeloma Market Size by Application
- 2.5.1 Global Immunotherapy Drugs for Multiple Myeloma Market Size Market Share by Application (2014-2019)
- 2.5.2 Global Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate by Application (2014-2019)
3 Global Immunotherapy Drugs for Multiple Myeloma by Players
- 3.1 Global Immunotherapy Drugs for Multiple Myeloma Market Size Market Share by Players
- 3.1.1 Global Immunotherapy Drugs for Multiple Myeloma Market Size by Players (2017-2019)
- 3.1.2 Global Immunotherapy Drugs for Multiple Myeloma Market Size Market Share by Players (2017-2019)
- 3.2 Global Immunotherapy Drugs for Multiple Myeloma Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
4 Immunotherapy Drugs for Multiple Myeloma by Regions
- 4.1 Immunotherapy Drugs for Multiple Myeloma Market Size by Regions
- 4.2 Americas Immunotherapy Drugs for Multiple Myeloma Market Size Growth
- 4.3 APAC Immunotherapy Drugs for Multiple Myeloma Market Size Growth
- 4.4 Europe Immunotherapy Drugs for Multiple Myeloma Market Size Growth
- 4.5 Middle East & Africa Immunotherapy Drugs for Multiple Myeloma Market Size Growth
5 Americas
- 5.1 Americas Immunotherapy Drugs for Multiple Myeloma Market Size by Countries
- 5.2 Americas Immunotherapy Drugs for Multiple Myeloma Market Size by Type
- 5.3 Americas Immunotherapy Drugs for Multiple Myeloma Market Size by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Key Economic Indicators of Few Americas Countries
6 APAC
- 6.1 APAC Immunotherapy Drugs for Multiple Myeloma Market Size by Countries
- 6.2 APAC Immunotherapy Drugs for Multiple Myeloma Market Size by Type
- 6.3 APAC Immunotherapy Drugs for Multiple Myeloma Market Size by Application
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 Key Economic Indicators of Few APAC Countries
7 Europe
- 7.1 Europe Immunotherapy Drugs for Multiple Myeloma by Countries
- 7.2 Europe Immunotherapy Drugs for Multiple Myeloma Market Size by Type
- 7.3 Europe Immunotherapy Drugs for Multiple Myeloma Market Size by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 7.9 Spain
- 7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
- 8.1 Middle East & Africa Immunotherapy Drugs for Multiple Myeloma by Countries
- 8.2 Middle East & Africa Immunotherapy Drugs for Multiple Myeloma Market Size by Type
- 8.3 Middle East & Africa Immunotherapy Drugs for Multiple Myeloma Market Size by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
- 9.2 Market Challenges and Impact
- 9.3 Market Trends
10 Global Immunotherapy Drugs for Multiple Myeloma Market Forecast
- 10.1 Global Immunotherapy Drugs for Multiple Myeloma Market Size Forecast (2019-2024)
- 10.2 Global Immunotherapy Drugs for Multiple Myeloma Forecast by Regions
- 10.2.1 Global Immunotherapy Drugs for Multiple Myeloma Forecast by Regions (2019-2024)
- 10.2.2 Americas Market Forecast
- 10.2.3 APAC Market Forecast
- 10.2.4 Europe Market Forecast
- 10.2.5 Middle East & Africa Market Forecast
- 10.3 Americas Forecast by Countries
- 10.3.1 United States Market Forecast
- 10.3.2 Canada Market Forecast
- 10.3.3 Mexico Market Forecast
- 10.3.4 Brazil Market Forecast
- 10.4 APAC Forecast by Countries
- 10.4.1 China Market Forecast
- 10.4.2 Japan Market Forecast
- 10.4.3 Korea Market Forecast
- 10.4.4 Southeast Asia Market Forecast
- 10.4.5 India Market Forecast
- 10.4.6 Australia Market Forecast
- 10.5 Europe Forecast by Countries
- 10.5.1 Germany Market Forecast
- 10.5.2 France Market Forecast
- 10.5.3 UK Market Forecast
- 10.5.4 Italy Market Forecast
- 10.5.5 Russia Market Forecast
- 10.5.6 Spain Market Forecast
- 10.6 Middle East & Africa Forecast by Countries
- 10.6.1 Egypt Market Forecast
- 10.6.2 South Africa Market Forecast
- 10.6.3 Israel Market Forecast
- 10.6.4 Turkey Market Forecast
- 10.6.5 GCC Countries Market Forecast
- 10.7 Global Immunotherapy Drugs for Multiple Myeloma Forecast by Type
- 10.8 Global Immunotherapy Drugs for Multiple Myeloma Forecast by Application
11 Key Players Analysis
- 11.1 Tonghua Dongbao Pharmaceutical
- 11.1.1 Company Details
- 11.1.2 Immunotherapy Drugs for Multiple Myeloma Product Offered
- 11.1.3 Tonghua Dongbao Pharmaceutical Immunotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
- 11.1.4 Main Business Overview
- 11.1.5 Tonghua Dongbao Pharmaceutical News
- 11.2 Sumitomo
- 11.2.1 Company Details
- 11.2.2 Immunotherapy Drugs for Multiple Myeloma Product Offered
- 11.2.3 Sumitomo Immunotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
- 11.2.4 Main Business Overview
- 11.2.5 Sumitomo News
- 11.3 Merck
- 11.3.1 Company Details
- 11.3.2 Immunotherapy Drugs for Multiple Myeloma Product Offered
- 11.3.3 Merck Immunotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
- 11.3.4 Main Business Overview
- 11.3.5 Merck News
- 11.4 Biogen
- 11.4.1 Company Details
- 11.4.2 Immunotherapy Drugs for Multiple Myeloma Product Offered
- 11.4.3 Biogen Immunotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
- 11.4.4 Main Business Overview
- 11.4.5 Biogen News
- 11.5 Schering-Plough
- 11.5.1 Company Details
- 11.5.2 Immunotherapy Drugs for Multiple Myeloma Product Offered
- 11.5.3 Schering-Plough Immunotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
- 11.5.4 Main Business Overview
- 11.5.5 Schering-Plough News
- 11.6 Roche
- 11.6.1 Company Details
- 11.6.2 Immunotherapy Drugs for Multiple Myeloma Product Offered
- 11.6.3 Roche Immunotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
- 11.6.4 Main Business Overview
- 11.6.5 Roche News
- 11.7 Glaxo
- 11.7.1 Company Details
- 11.7.2 Immunotherapy Drugs for Multiple Myeloma Product Offered
- 11.7.3 Glaxo Immunotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
- 11.7.4 Main Business Overview
- 11.7.5 Glaxo News
- 11.8 Chiron
- 11.8.1 Company Details
- 11.8.2 Immunotherapy Drugs for Multiple Myeloma Product Offered
- 11.8.3 Chiron Immunotherapy Drugs for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2019)
- 11.8.4 Main Business Overview
- 11.8.5 Chiron News
12 Research Findings and Conclusion
According to this study, over the next five years the Immunotherapy Drugs for Multiple Myeloma market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Immunotherapy Drugs for Multiple Myeloma business, shared in Chapter 3.
This report presents a comprehensive overview, market shares and growth opportunities of Immunotherapy Drugs for Multiple Myeloma market by product type, application, key companies and key regions.
This study considers the Immunotherapy Drugs for Multiple Myeloma value generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
INF-α
IL-6
Other
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Hospital
Drug Center
Clinic
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Tonghua Dongbao Pharmaceutical
Sumitomo
Merck
Biogen
Schering-Plough
Roche
Glaxo
Chiron
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Immunotherapy Drugs for Multiple Myeloma market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Immunotherapy Drugs for Multiple Myeloma market by identifying its various subsegments.
Focuses on the key global Immunotherapy Drugs for Multiple Myeloma players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Immunotherapy Drugs for Multiple Myeloma with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Immunotherapy Drugs for Multiple Myeloma submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.